7th Drug Formulation, Solubility & Bioavailability Summit
March 26, 2018 - March 28, 2018
When over 80% of APIs in development are poorly water-soluble, drug companies must rely increasingly on new formulation and delivery strategies to maximize bioavailability. ExL’s 7th Drug Formulation, Solubility & Bioavailability conference helps you recognize the precise thresholds where an enabled formulation becomes necessary, as well as determine which method to use and how to predict and gauge its success. This event provides you with an unmatched focus on the latest technologies and team skills that you need to gather and interpret first-in-human results and accelerate time-to-market.
Pion will be exhibiting.
8:45 AM - 5:00 PM
Poor exposure following oral administration is a common challenge facing discovery programs and consequently a frequent focus for DMPK scientists. Frequently, potent compounds cannot be further developed due to less-than-ideal ADME (absorption, distribution, metabolism, and excretion) properties that prevent the compounds to be available following oral administration. Beyond the discovery phase the importance of understanding and optimizing oral exposure continues in the preclinical and ultimately clinical phases of drug development. Inadequate oral exposure could be due to suboptimal physicochemical properties, or problems in absorption from the gut, or first-pass metabolism in the gut and liver, or high intrinsic clearance of the compounds.
The focus of this workshop/symposium is on: 1) to identify and learn about the issues that contribute to low oral exposure, 2) to discuss approaches that one could use to overcome those challenges, 3) to present additional methodologies that can aid in solving exposure problems and 4) to provide suggestions on how to work with partners in Medicinal Chemistry and Biological Sciences within Project Teams.
Pion will be exhibiting. Visit us at the Pion Inc. table.